Analyst Price Target is $5.00
▲ +60.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 60.77% upside from the last price of $3.11.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Entasis Therapeutics. This Buy consensus rating has held steady for over two years.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.